Biotron Limited (AU:BIT)
ASX:BIT
Top Page
Biotron
(Sydney:BIT)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.01
â–˛(10.00% Upside)
Action:UpgradedDate:12/30/25
The score is held down primarily by continued losses and persistently negative operating/free cash flow despite improved FY2025 results. A low-debt balance sheet is a meaningful positive, while valuation is constrained by a negative P/E and technicals cannot be assessed due to missing indicators.
Positive Factors
Low Debt Levels
A low-debt balance sheet reduces financial risk, providing Biotron with greater flexibility to invest in R&D and strategic initiatives without the burden of high interest expenses.
Negative Factors
Negative Cash Flow
Persistent negative cash flow indicates ongoing reliance on external funding, which could limit Biotron's ability to sustain operations and invest in growth without raising additional capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Debt Levels
A low-debt balance sheet reduces financial risk, providing Biotron with greater flexibility to invest in R&D and strategic initiatives without the burden of high interest expenses.
Read all positive factors
Biotron (BIT) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.40M
Dividend YieldN/A
Average Volume (3M)1.60M
Price to Earnings (P/E)―
Beta (1Y)1.38
Revenue GrowthN/A
EPS Growth87.88%
CountryAU
Employees4
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,701,866,000
10 Day Avg. Volume3,265,462
30 Day Avg. Volume1,601,469
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)3.63
Price to Sales (P/S)1.10
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotron Business Overview & Revenue Model
Company Description
Biotron Limited (BIT) is a biotechnology company focused on the development of novel therapeutics for the treatment of serious viral infections. The company operates primarily in the pharmaceutical and biotechnology sectors, with a core emphasis o...
How the Company Makes Money
Biotron Limited generates revenue primarily through research and development partnerships, licensing agreements, and milestone payments related to the commercialization of its proprietary antiviral compounds. The company collaborates with pharmace...
Biotron Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -868.00 | 1.81M | 1.65M | 1.43M | 1.56M | 1.46M |
| Gross Profit | -1.65K | 1.81M | 1.65M | 1.39M | 1.51M | 1.41M |
| EBITDA | -1.93M | -333.81K | -5.04M | -4.88M | -2.73M | -4.56M |
| Net Income | -1.94M | -318.57K | -3.44M | -3.49M | -2.78M | -3.19M |
Balance Sheet | ||||||
| Total Assets | 3.86M | 980.40K | 493.48K | 4.14M | 1.91M | 4.33M |
| Cash, Cash Equivalents and Short-Term Investments | 1.64M | 931.68K | 393.20K | 3.98M | 1.74M | 4.21M |
| Total Debt | 0.00 | 0.00 | 7.13K | 45.27K | 77.24K | 6.35K |
| Total Liabilities | 1.16M | 428.51K | 737.51K | 962.49K | 813.57K | 463.51K |
| Stockholders Equity | 2.70M | 551.89K | -244.03K | 3.17M | 1.09M | 3.86M |
Cash Flow | ||||||
| Free Cash Flow | -1.92M | -568.87K | -3.57M | -3.29M | -2.44M | -3.41M |
| Operating Cash Flow | -1.92M | -565.80K | -3.57M | -3.29M | -2.44M | -3.41M |
| Investing Cash Flow | 111.51K | -3.07K | 0.00 | 0.00 | 0.00 | -5.72K |
| Financing Cash Flow | 2.58M | 1.11M | -22.62K | 5.53M | -33.17K | -36.96K |
Biotron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$76.38M | 19.71 | 17.85% | ― | 41.57% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$214.67M | 27.58 | -15.96% | ― | -40.74% | -21.21% | |
46 Neutral | AU$5.40M | -1.22 | -119.12% | ― | ― | 87.88% | |
44 Neutral | AU$9.76M | -1.25 | -140.35% | ― | ― | ― | |
43 Neutral | AU$9.47M | -1.29 | -43.95% | ― | 48.63% | 25.66% | |
41 Neutral | AU$131.58M | -2.84 | 279.21% | ― | ― | 0.66% |
* Healthcare Sector Average
AU:BIT
Biotron
―
―
―
AU:SPL
Starpharma Holdings Limited
0.51
0.41
431.25%
AU:IMC
Immuron Limited
0.03
-0.03
-51.67%
AU:BGT
Bio-Gene Technology Ltd.
0.03
<0.01
10.34%
AU:BIO
Biome Australia Ltd
0.34
-0.10
-22.99%
AU:RCE
Recce Pharmaceuticals Ltd.
0.46
0.13
41.74%
Biotron Corporate Events
Biotron Directors Lift Holdings Through Rights Issue Participation
Dec 23, 2025
Biotron Limited has notified the ASX of changes in directors’ interests in the company’s securities, in compliance with listing requirements for disclosure of director shareholdings. The filing shows chairman Michael J. Hoy increased h...
Biotron Seeks ASX Quotation for 181.7 Million New Options
Dec 23, 2025
Biotron Limited has lodged an application with the ASX for quotation of 181,666,666 new options (ASX code: BITO) expiring on 24 November 2027, with an issue date of 19 December 2025. The move significantly increases the volume of listed options ov...
Biotron Withdraws Appendix 3G, To Refile Equity Notice as Appendix 2A
Dec 23, 2025
Biotron Limited has withdrawn a previously lodged Appendix 3G notice relating to the issue, conversion or payment up of unquoted securities and will replace it with an Appendix 2A. The change indicates an administrative correction in how the compa...
Biotron Appoints Veteran Life Sciences Executive Paul Kasian as Non-Executive Director
Dec 23, 2025
Biotron Limited has appointed experienced life sciences executive and board director Dr Paul Kasian as a Non-Executive Director, effective 23 December 2025. With more than three decades of leadership across biotechnology, diagnostics, therapeutics...
Biotron Shares Reinstated to Quotation on ASX
Dec 21, 2025
Biotron Limited has had its ordinary shares (trading under the ASX code BITO) reinstated to quotation on the Australian Securities Exchange following confirmation that the company has met ASX Listing Rule 2.5 requirements. The return to trading st...
Biotron Issues 181.7 Million Unquoted Options Expiring in 2027
Dec 19, 2025
Biotron Limited has notified the Australian Securities Exchange of the issue of 181,666,666 unquoted options, exercisable by 24 November 2027. The large grant of deferred options signals a significant equity-based component in the company’s ...
Biotron Discloses Top 20 Holders and Distribution of Newly Listed Options
Dec 19, 2025
Biotron Limited has released details of its top 20 option holders and the distribution schedule for its newly listed options on the ASX, issued in connection with recent Appendixes 2A. The disclosure enhances transparency around the company’...
Biotron Raises $645,861 via Rights Issue to Advance Hepatitis B Program
Dec 19, 2025
Biotron Limited has completed its non-renounceable rights issue, raising $645,861 through the issue of 215,286,751 fully paid ordinary shares and 107,643,345 options, which will trade on the ASX under the code BITO. The capital will fund toxicolog...
Biotron Limited’s BITO Securities Suspended by ASX
Dec 14, 2025
Biotron Limited’s securities under the code BITO have been suspended from quotation by ASX Limited due to compliance issues with Listing Rule 2.5. This suspension is specific to the BITO class and does not affect other securities of Biotron ...
Biotron Limited Announces Quotation of New Securities on ASX
Dec 10, 2025
Biotron Limited has announced the quotation of 33,333,333 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective December 10, 2025. This move is part of a previously announced transaction and is expected to enhance B...
Biotron Limited Announces Quotation of 500 Million Securities on ASX
Dec 10, 2025
Biotron Limited announced the quotation of 500,000,000 ordinary fully paid securities on the ASX, as part of a transaction previously disclosed. This move is likely to enhance the company’s financial flexibility and market presence, potentia...
Biotron Limited Issues 500,000 Unquoted Performance Shares
Dec 10, 2025
Biotron Limited announced the issuance of 500,000 unquoted performance shares as part of a previously disclosed transaction. This move is expected to enhance the company’s operational capabilities and strengthen its position in the biotechno...
Biotron Completes Acquisition of Sedarex Limited
Dec 10, 2025
Biotron Limited has successfully completed the acquisition of Sedarex Limited, a move approved by its shareholders. This acquisition involves the issuance of 500 million consideration shares and 33,333,333 facilitation shares, with certain shares ...
Biotron Completes $1 Million Placement to Fund New Acquisition
Dec 2, 2025
Biotron Limited has successfully completed Tranche 2 of its Placement, raising a total of $1 million to fund the development of products from its recent acquisition of Sedarex Limited. This acquisition and funding are pivotal for Biotron, as they ...
Biotron Limited Issues 15 Million Unquoted Equity Securities
Dec 2, 2025
Biotron Limited announced the issuance of 15,000,000 unquoted equity securities as part of a previously announced transaction. This move could potentially impact the company’s financial structure and market positioning, as it may provide add...
Biotron Limited Announces Quotation of New Securities on ASX
Dec 2, 2025
Biotron Limited has announced the quotation of 134,246,669 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This development is expected to enhance the company’s financi...
Biotron Limited Opens Non-Renounceable Entitlement Offer
Nov 26, 2025
Biotron Limited has announced the dispatch of its prospectus and the opening of a non-renounceable entitlement offer, which was initially announced on October 15, 2025. The offer includes the issuance of attaching options and is aimed at eligible ...
Biotron Limited Announces Details of Rights Issue
Nov 19, 2025
Biotron Limited has announced details regarding its rights issue, initially disclosed on 15 October 2025. The rights issue includes an offer of one attaching option for every two shares issued, with fractions of attaching options being rounded dow...
Biotron Announces AGM Outcomes and Board Elections
Nov 17, 2025
Biotron held its Annual General Meeting where several key resolutions were voted on, including the adoption of the Remuneration Report and the re-election of directors Robert B. Thomas and Michael J. Medway. Additionally, Peter Scott and Hugh Miln...
Biotron Pursues Growth with Sedarex Acquisition Amidst COVID-19 Trial Setback
Nov 16, 2025
Biotron faced a challenging year after its COVID-19 trial, BIT225-012, did not meet primary efficacy endpoints, highlighting the risks in late-stage drug development. Despite this setback, Biotron is pursuing growth and diversification through the...
Biotron’s BIT-HBV001 Shows Promise in Hepatitis B Treatment
Nov 13, 2025
Biotron Limited has announced significant progress in its Hepatitis B Virus (HBV) program, highlighting the efficacy of its lead drug, BIT-HBV001. The drug has demonstrated superior anti-HBV activity compared to the current first-line treatment, T...
Biotron Limited Engages Investors with Strategic Presentation
Nov 11, 2025
Biotron Limited’s Managing Director, Michelle Miller, presented a PowerPoint presentation to investors, which was announced via ASX. This presentation is part of Biotron’s ongoing efforts to engage with stakeholders and provide updates...
Biotron’s Strategic Acquisition of Sedarex Limited Promises Growth
Nov 11, 2025
Biotron has announced a strategic acquisition of Sedarex Limited, which owns SedRx, a patented next-generation general anesthetic formulation. This acquisition is expected to significantly enhance Biotron’s growth and diversification prospec...
Biotron Limited Announces Investor Webinar on Sedarex Acquisition
Nov 7, 2025
Biotron Limited has announced an upcoming investor webinar scheduled for November 11, 2025, where Managing Director Michelle Miller will discuss the company’s recent acquisition of Sedarex Limited. This strategic move is expected to enhance ...
Biotron Limited Issues Supplementary Notice for AGM with Potential Governance Changes
Oct 31, 2025
Biotron Limited has issued a supplementary notice for its upcoming Annual General Meeting, scheduled for November 17, 2025. The notice includes an additional resolution, known as the Spill Resolution, which could lead to an extraordinary general m...
Biotron Advances Antiviral Research and Expands with Sedarex Acquisition
Oct 30, 2025
Biotron Limited has made significant strides in the quarter ending September 2025, focusing on the assessment of its lead Hepatitis B virus compound in animal models and advancing its commercialization efforts with C14 Consulting Group. The compan...
Biotron Limited Raises $597,260 Through Share Placement
Oct 22, 2025
Biotron Limited has successfully issued 199,086,664 new fully paid ordinary shares at $0.003 per share, raising $597,260 before costs. This strategic move, executed under the company’s 15% capacity pursuant to ASX Listing Rule 7.1, allows fo...
Biotron Limited Announces Quotation of New Securities on ASX
Oct 22, 2025
Biotron Limited has announced the quotation of 199,086,664 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of previously announced transactions. This move is expected to enhance Biotron’s market presence an...
Biotron Limited Announces Proposed Issue of 500,000 Performance Shares
Oct 17, 2025
Biotron Limited has announced a proposed issue of 500,000 performance shares, with a planned issue date of November 24, 2025. This strategic move is part of the company’s efforts to enhance its market presence and operational capabilities, p...
Biotron Limited Updates Securities Issuance Plan
Oct 17, 2025
Biotron Limited announced an update to its previous securities issuance plan, splitting the consideration shares into Ordinary Shares and Performance Shares. This strategic move is expected to enhance the company’s financial flexibility and ...
Biotron Limited Acquires Sedarex Limited to Bolster Viral Drug Development
Oct 17, 2025
Biotron Limited has announced the acquisition of Sedarex Limited, with the consideration for the purchase consisting of 500 million ordinary Biotron shares and performance shares valued at $500,000. This acquisition is expected to enhance Biotron&...
Biotron Releases 2025 Annual Report and AGM Notice
Oct 17, 2025
Biotron has released its Annual Report for the fiscal year ending June 30, 2025, along with the notice for its upcoming Annual General Meeting scheduled for November 17, 2025. This announcement is significant as it provides stakeholders with insig...
Biotron Limited Announces Acquisition of Sedarex and Capital Raising
Oct 15, 2025
Biotron Limited has announced the acquisition of Sedarex Limited and a capital raising initiative, which was detailed in an investor webinar led by Managing Director Michelle Miller. This strategic move is expected to enhance Biotron’s marke...
Biotron Limited Announces Proposed Securities Issue to Bolster Antiviral Research
Oct 15, 2025
Biotron Limited has announced a proposed issue of securities, comprising 166,666,666 options and 333,333,333 fully paid ordinary shares, with a planned issue date of November 24, 2025. This strategic move is likely aimed at raising capital to supp...
Biotron Limited Announces Major Securities Issuance
Oct 15, 2025
Biotron Limited has announced a proposed issue of 666,666,666 fully paid ordinary securities, scheduled for issuance on November 24, 2025. This move is expected to enhance the company’s capital base, potentially strengthening its market posi...
Biotron Limited Announces Proposed Issue of 15 Million Securities
Oct 15, 2025
Biotron Limited announced a proposed issue of 15 million new securities, with the issuance date set for November 24, 2025. This strategic move is expected to bolster the company’s financial position, potentially enhancing its capacity to adv...
Biotron Limited Announces Proposed Securities Issue
Oct 15, 2025
Biotron Limited has announced a proposed issue of 33,333,333 fully paid ordinary securities, with the issuance date set for November 24, 2025. This move is part of a placement or other type of issue, which could potentially enhance the companyR...
Biotron Limited Announces Proposed Securities Issue to Support Growth
Oct 15, 2025
Biotron Limited has announced a proposed issue of securities, including options and ordinary fully paid shares, as part of a standard pro rata issue. This move is expected to enhance the company’s financial flexibility and support its ongoin...
Biotron Expands Portfolio with Sedarex Acquisition and Capital Raising
Oct 15, 2025
Biotron Limited has announced the acquisition of Sedarex Limited, which holds global patents for SedRx, a safer next-generation general anaesthetic. This acquisition is supported by a $2.5 million capital raising initiative, led by Peak Asset Mana...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.